Erlotinib 150mg Tablet

Erlotinib 150mg Tablet is a prescription targeted anticancer product used in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. This oral therapy helps manage cancer progression by specifically targeting and blocking the epidermal growth factor receptor (EGFR) signaling pathways responsible for tumor growth.

The active ingredient, erlotinib, works as an EGFR inhibitor to disrupt the communication that cancer cells need to grow and multiply. By interfering with these signals, erlotinib helps slow tumor growth, making it an effective option for patients as part of targeted therapy protocols under strict oncologist supervision.

Erlotinib 150 mg Tablet is administered orally under the guidance of a healthcare professional and is typically used in combination with other anticancer therapies when prescribed. This prescription-only product ensures consistent potency, safety, and therapeutic effectiveness in the treatment of advanced lung and pancreatic cancers.

Product Features

• Targeted anticancer therapy tablet
• Contains Erlotinib 150 mg
• EGFR tyrosine kinase inhibitor
• Used in NSCLC and pancreatic cancer
• Oral tablet dosage form
• Suitable for long-term targeted therapy
• Manufactured under strict pharmaceutical quality standards
• Prescription-required oncology medicine

How It Helps

• Blocks EGFR signals to slow cancer cell growth
• Helps manage non-small cell lung cancer (NSCLC) and pancreatic cancer
• Supports long-term targeted therapy for advanced cancers
• Enhances the effectiveness of combination cancer treatment regimens